[go: up one dir, main page]

GB0522932D0 - PKC412 in treatment of atypical chronic myeloid leukemia - Google Patents

PKC412 in treatment of atypical chronic myeloid leukemia

Info

Publication number
GB0522932D0
GB0522932D0 GBGB0522932.3A GB0522932A GB0522932D0 GB 0522932 D0 GB0522932 D0 GB 0522932D0 GB 0522932 A GB0522932 A GB 0522932A GB 0522932 D0 GB0522932 D0 GB 0522932D0
Authority
GB
United Kingdom
Prior art keywords
pkc412
treatment
myeloid leukemia
chronic myeloid
atypical chronic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0522932.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southampton
Original Assignee
University of Southampton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southampton filed Critical University of Southampton
Priority to GBGB0522932.3A priority Critical patent/GB0522932D0/en
Publication of GB0522932D0 publication Critical patent/GB0522932D0/en
Priority to PCT/GB2006/004210 priority patent/WO2007054717A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GBGB0522932.3A 2005-11-10 2005-11-10 PKC412 in treatment of atypical chronic myeloid leukemia Ceased GB0522932D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0522932.3A GB0522932D0 (en) 2005-11-10 2005-11-10 PKC412 in treatment of atypical chronic myeloid leukemia
PCT/GB2006/004210 WO2007054717A2 (en) 2005-11-10 2006-11-10 STAUROSPORINE DERIVATIVES FOR THE TREATMENT OF LEUKEMIA CHARACTERISED BY A SPTBNl -FLT3 MUTATION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0522932.3A GB0522932D0 (en) 2005-11-10 2005-11-10 PKC412 in treatment of atypical chronic myeloid leukemia

Publications (1)

Publication Number Publication Date
GB0522932D0 true GB0522932D0 (en) 2005-12-21

Family

ID=35516689

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0522932.3A Ceased GB0522932D0 (en) 2005-11-10 2005-11-10 PKC412 in treatment of atypical chronic myeloid leukemia

Country Status (2)

Country Link
GB (1) GB0522932D0 (en)
WO (1) WO2007054717A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019108492A1 (en) * 2017-11-30 2019-06-06 Albert Einstein College Of Medicine, Inc. Prevention and treatment of viral infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6846630B2 (en) * 1996-10-18 2005-01-25 Takara Shuzo Co., Ltd. Nucleic acid encoding receptor type protein kinase
IL161156A0 (en) * 2001-10-30 2004-08-31 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
CA2533861A1 (en) * 2003-08-08 2005-02-17 Novartis Ag Combinations comprising staurosporines

Also Published As

Publication number Publication date
WO2007054717A3 (en) 2007-08-02
WO2007054717A2 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
IL248204A0 (en) Combination treatment of cd38-expressing tumors
IL188430A0 (en) Treatment of tumors
IL191832A0 (en) Pyridiazinone derivatives for the treatment of tumours
GB0517361D0 (en) Therapeutic foam
PL2101731T3 (en) Endoxifen for use in the treatment of cancer
EP2049139A4 (en) Treatment of ras-expressing tumors
ZA200809529B (en) Melatonin agonist treatment
HUE055524T2 (en) Treatment of imatinib resistant chronic myelogenous leukemia having the mutaton 1457t>c in the bcrabl gene using the compound bosutinib
ZA200901452B (en) Treatment of vertigo with acetyl-L-leucine
GB0506835D0 (en) Therapeutic use of nefopam
GB0509819D0 (en) Therapeutic foam
GB0523026D0 (en) Patient table
GB0524427D0 (en) Use of receptor ligands in threapy
GB0522932D0 (en) PKC412 in treatment of atypical chronic myeloid leukemia
GB0522853D0 (en) PKC412 in treatment of atypical chronic myeloid leukemia
GB0517387D0 (en) Combinations for the treatment of cancer
GB0609048D0 (en) Table structure
GB0518720D0 (en) Therapeutic combination
GB0501655D0 (en) Therapeutic use
IL180709A0 (en) Treatment of tumours
GB0515703D0 (en) Therapeutic use of nefopam
GB0522935D0 (en) FLT3 modulators in treatment of atypical chronic myeloid leukemia
GB2432516B (en) Footstool
GB0623492D0 (en) Therapeutic G-quadruplex ligands
ZAA200501736S (en) Pitchers

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)